![David Festus Charles Moffat](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Festus Charles Moffat
Private Equity Investor bei General Inception
Ursprung des Netzwerks ersten Grades von David Festus Charles Moffat
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
General Inception
![]() General Inception Investment ManagersFinance General Inception Management LLC (General Inception Management) is a venture capital firm founded in 2020 by Vikram Chaudhery, Paul A. Conley and Jim Buzzitta. The firm is headquartered in San Francisco, California.
17
| Holding Company | Investment Managers | 17 |
Chroma Therapeutics Ltd.
![]() Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom.
9
| Private Company | Biotechnology | 9 |
Macrophage Pharma Ltd.
![]() Macrophage Pharma Ltd. BiotechnologyHealth Technology Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom.
6
| Holding Company | Biotechnology | 6 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von David Festus Charles Moffat
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Chairman Chief Investment Officer | |
Paladin Capital Group
![]() Paladin Capital Group Investment ManagersFinance Paladin Capital Group (Paladin Capital) is a private equity subsidiary of Penn Ave Investments LLC founded by Mark Maloney and Michael Steed in 2001. The firm is headquartered in Washington, DC with offices in New York City, Silicon Valley, London and Luxembourg. | Investment Managers | Private Equity Investor Private Equity Investor | |
The University of Chicago | College/University | Undergraduate Degree Doctorate Degree | |
INSEAD | College/University | Masters Business Admin Masters Business Admin | |
University of California, Berkeley | College/University | Doctorate Degree Doctorate Degree | |
University of California San Diego | College/University | Doctorate Degree Undergraduate Degree | |
The University of Nottingham | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree | |
University College London | College/University | Undergraduate Degree Undergraduate Degree | |
University of Utrecht | College/University | Doctorate Degree Doctorate Degree | |
NDDO Oncology BV
![]() NDDO Oncology BV Miscellaneous Commercial ServicesCommercial Services Part of Syneos Health, Inc., NDDO Oncology BV provides product development support to pharmaceutical and biotechnology companies. The company is based in Amsterdam, Netherlands. The Dutch company was founded by Herbert Michael Pinedo. NDDO Oncology was acquired by Syneos Health NC LLC, part of Syneos Health, Inc. from December 31, 2010 on December 01, 2005. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
University College Cork | College/University | Graduate Degree | |
Nabriva Therapeutics GmbH
![]() Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Pharmaceuticals: Major | Corporate Officer/Principal | |
THERMO FISHER SCIENTIFIC | Medical Specialties | Director/Board Member Corporate Officer/Principal | |
Aescap Venture Management BV
![]() Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Investment Managers | Private Equity Investor | |
Symphogen A/S
![]() Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Founder Chairman Director/Board Member Chief Operating Officer | |
NATERA, INC. | Medical Specialties | Director/Board Member Corporate Officer/Principal | |
ISA Pharmaceuticals BV
![]() ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Chief Executive Officer | |
ORCA Therapeutics BV
![]() ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | Pharmaceuticals: Generic | Director/Board Member | |
MERUS N.V. | Biotechnology | Director/Board Member | |
The Bioindustry Association
![]() The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
The European CanCer Organisation | Corporate Officer/Principal | ||
InteRNA Technologies BV
![]() InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | Biotechnology | Chairman Director/Board Member | |
ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member | |
Netherlands Society of Gene Therapy | Corporate Secretary | ||
Macrotarg Ltd.
![]() Macrotarg Ltd. BiotechnologyHealth Technology Macrotarg Ltd. is a biotechnology research and British experimental development company founded in 2007. The private company is based in Winnersh, UK. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
SomantiX BV
![]() SomantiX BV Miscellaneous Commercial ServicesCommercial Services SomantiX BV develops imaging and therapy of cancer through targeting of tumor blood vessels. The firm offers Somantix’ screening platform which is in combination with the binder generation technologies that allows validation of new therapeutic targets and development of new cancer medicines. The company was founded in 2008 and is headquartered in Utrecht, Netherlands. | Miscellaneous Commercial Services | Chief Executive Officer | |
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Cristal Delivery BV
![]() Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
Epidarex Capital Partners LLC
![]() Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland. | Investment Managers | Private Equity Investor | |
Rijksinstituut Voor Volksgezondheid En Milieu | Corporate Officer/Principal | ||
SynAffix BV
![]() SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Biotechnology | Director/Board Member | |
Forendo Pharma Oy
![]() Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Director/Board Member | |
Mimetas BV
![]() Mimetas BV BiotechnologyHealth Technology Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
PROGYNY, INC. | Miscellaneous Commercial Services | Director/Board Member | |
IONpath, Inc.
![]() IONpath, Inc. Medical/Nursing ServicesHealth Services IONpath, Inc. transforms pathology with multiplexed ion beam imaging. The company was founded by Michael Angelo, Sean Bendall, Harris Fienberg and Gerry Noland and is headquartered in San Mateo, CA. | Medical/Nursing Services | Director/Board Member Sales & Marketing | |
Inthera Bioscience AG
![]() Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Biotechnology | Director/Board Member Director/Board Member | |
Merck Ventures BV
![]() Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor | |
Mironid Ltd.
![]() Mironid Ltd. Pharmaceuticals: MajorHealth Technology Mironid Ltd. develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. The company was founded by Miles Houslay, Paul Barton Rodgers, Elizabeth Fairley, Julia Adam, David Adams and Nigel Pyne in 2014 and is headquartered in North Lanarkshire, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
STORM Therapeutics Ltd.
![]() STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
Edinburgh Molecular Imaging Ltd.
![]() Edinburgh Molecular Imaging Ltd. Medical SpecialtiesHealth Technology Edinburgh Molecular Imaging Ltd. develops optical molecular imaging technology, which includes optical imaging, cancer imaging and lung imaging. The firm's molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. The company was founded by Chris Haslett, Kev Dhaliwal and Mark Bradley in February 2014 and is headquartered in Edinburgh, the United Kingdom. | Medical Specialties | Director/Board Member | |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
iOnctura SA
![]() iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
Ribometrix, Inc.
![]() Ribometrix, Inc. Pharmaceuticals: MajorHealth Technology Ribometrix, Inc. develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease. The company was founded by Kevin Weeks and Katie Warner and is headquartered in Greenville, NC. | Pharmaceuticals: Major | Director/Board Member | |
Adorx Therapeutics Ltd.
![]() Adorx Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Adorx Therapeutics Ltd. provides biotechnology, health care and therapeutics services. The company is headquartered in Edinburgh, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Genoa Ventures LLC
![]() Genoa Ventures LLC Investment ManagersFinance Genoa Ventures LLC (Genoa Ventures) is an independent private equity/venture capital firm founded in 2018 by Jenny Rooke. The firm is headquartered in San Francisco, California. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor Corporate Officer/Principal | |
Outrun Therapeutics Ltd.
![]() Outrun Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Outrun Therapeutics Ltd. is a British biotechnology company founded in 2019 that develops a platform for drug discovery. | Miscellaneous Commercial Services | Director/Board Member |
Statistik
International
Niederlande | 16 |
Vereinigtes Königreich | 15 |
Vereinigte Staaten | 11 |
Dänemark | 4 |
Frankreich | 3 |
Sektoral
Health Technology | 26 |
Consumer Services | 9 |
Commercial Services | 8 |
Finance | 7 |
Health Services | 2 |
Operativ
Director/Board Member | 206 |
Corporate Officer/Principal | 53 |
Chairman | 41 |
Chief Executive Officer | 30 |
Private Equity Investor | 29 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Göran Albert Ando | 44 |
Paul Conley | 39 |
Timothy Haines | 36 |
Judith Ann Hemberger | 26 |
Anker Gunvald Lundemose | 25 |
Ian James Nicholson | 20 |
Klaus Veitinger | 18 |
Hakan Goker | 18 |
Elizabeth Ann Roper | 16 |
Michael G. Moore | 16 |
François Valencony | 16 |
Mark R.L. Krul | 16 |
Richard Bungay | 14 |
Mourad Yesayan | 13 |
Venkat Reddy | 9 |
- Börse
- Insiders
- David Festus Charles Moffat
- Unternehmensverbindungen